Patient experience and attitudes toward addressing the cost of breast cancer care

Oncologist

Volumn 19, Issue 11, 2014, Pages 1135-1140

  Irwin, Blair ^a   Kimmick, Gretchen ^a   Altomare, Ivy ^a   Marcom, P Kelly ^a   Houck, Kevin ^a   Zafar, S Yousuf ^a   Peppercorn, Jeffrey ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cost of illness; Drug costs; Health care costs; Health care disparities; Neoplasm

Indexed keywords

GENERIC DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; COLORECTAL CANCER; COST CONTROL; DECISION MAKING; DIGESTIVE SYSTEM CANCER; EXPERIENCE; FEMALE; FINANCIAL DEFICIT; GOVERNMENT; HEALTH CARE COST; HEALTH CARE SURVEY; HEALTH INSURANCE; HUMAN; INCHARGE FINANCIAL DISTRESS FINANCIAL WELL BEING SCALE; INCOME; LEUKEMIA; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT ATTITUDE; PROSTATE CANCER; QUESTIONNAIRE; BREAST TUMOR; DOCTOR PATIENT RELATION; DRUG COST; ECONOMICS; INFORMATION PROCESSING; MIDDLE AGED; ONCOLOGY; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DATA COLLECTION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; LOGISTIC MODELS; MEDICAL ONCOLOGY; MIDDLE AGED; PHYSICIAN-PATIENT RELATIONS;

EID: 84908548883     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0117     Document Type: Article

References (23)

1. Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-128.
2. Warren JL, Yabroff KR, Meekins A et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100:888-897.
3. Davidoff AJ, Erten M, Shaffer T et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 2013;119:1257-1265.
4. Bullock AJ, Hofstatter EW, Yushak ML et al. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract 2012;8:e50-e58.
5. Eichholz M, Pevar J, Bernthal T. Perspectives on the financial burden of cancer care: Concurrent surveys of patients (Pts), caregivers (CGs), and oncology social workers (OSWs). J Clin Oncol 2010;28(suppl):9111a.
6. Zafar SY, Peppercorn JM, Schrag D et al. The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. The Oncologist 2013; 18:381-390.
7. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 2009;27:3868-3874.
8. Prawitz AD, Garman ET, Sorhaindo B et al. The InCharge Financial Distress/Financial Well-Being Scale: Establishing validity and reliability. Proc Assoc Financial Counseling Planning Education 2006;17:34-50.
9. Schoen C, Osborn R, Squires D et al. How health insurance design affects access to care and costs, by income, in eleven countries. Health Aff (Millwood) 2010;29:2323-2334.
10. Zullig LL, Peppercorn JM, Schrag D et al. Financial distress, use of cost-coping strategies, and adherence to prescription medication among participants with cancer. J Oncol Pract 2013;9:60s-63s.
11. Nekhlyudov L, Madden J, Graves AJ et al. Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. J Cancer Surviv 2011;5:395-404.
12. Hong J, Reed C, Novick D et al. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res 2011;190:110-114.
13. Heisler M, Choi H, Rosen AB et al. Hospital-izationsanddeathsamongadults with cardiovascular disease who underuse medications because of cost: A longitudinal analysis. Med Care 2010;48:87-94.
14. Shih YC, Ganz PA, Aberle D et al. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol 2013;31: 4151-4157.
15. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933-980.
16. Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: A pilot survey. J Clin Oncol 2007;25:233-237.
17. Henrikson NB, Tuzzio L, Loggers ET et al. Patient and oncologist discussions about cancer care costs. Support Care Cancer 2014;22:961-967.
18. Jung OS, Guzzo T, Lee D et al. Out-of-pocket expenses and treatment choice for men with prostate cancer. Urology 2012;80:1252-1257.
19. Claxton K, Briggs A, Buxton MJ et al. Value based pricing for NHS drugs: An opportunity not to be missed? BMJ 2008;336:251-254.
20. Hawkes N. NICE to set out how it will judge social benefits of drugs. BMJ 2014;348:g370.
21. Linley WG, Hughes DA. Societal views on N ICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: A cross-sectional survey of 4118 adults in Great Britain. Health Econ2013;22: 948-964.
22. Ramsey SD, Ganz PA, Shankaran V et al. Addressing the American health-care cost crisis: Role of the oncology community. J Natl Cancer Inst 2013;105:1777-1781.
23. Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 2012;30: 1715-1724.